Drug intelligence / Profile preview

GORD167

Development stage: Unknown
Lead developer: Gordion Bioscience
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GORD167 is a bispecific antibody being developed by Gordion Bioscience to treat tumors that are non-responsive to standard PD-L1 checkpoint inhibitor therapies. Developed using the company's machine learning platform and patient-derived tumor genomic data, the antibody is designed to simultaneously inhibit primary drug targets and their compensatory resistance mechanisms. While the specific molecular targets remain undisclosed, the therapeutic strategy focuses on overcoming mechanisms of resistance in PD-L1 non-responding patients. GORD167 is currently in Phase 1 clinical development.

Beyond the preview

Go deeper on GORD167.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GORD167.

Explore the full profile